Discontinuing Anti-VEGF Therapy in Patients with Neovascular Age-Related Macular Degeneration That Remains Inactive with Treatment at the Maximum Injection Interval
Günhal Şatırtav, Monica Karin Lövestam-Adrian, Woohyok Chang, Martín Charles, Lee-Jen Chen, Chui Ming Gemmy Cheung, Laurent Kodjikian, Masahito Ohji, Martin Zinkernagel, Sebastian Wolf · 2026
Read Discontinuing Anti-VEGF Therapy in Patients with Neovascular Age-Related Macular Degeneration That Remains Inactive with Treatment at the Maximum Injection Interval by Günhal Şatırtav, Monica Karin Lövestam-Adrian, Woohyok Chang, Martín Charles, Lee-Jen Chen, Chui Ming Gemmy Cheung, Laurent Kodjikian, Masahito Ohji, Martin Zinkernagel, Sebastian Wolf (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13318646.txt.
Description
Günhal Şatırtav leads an international expert group whose 2026 review gives guidance on when injections for wet age-related macular degeneration can safely stop. The Vision Academy panel read the literature and agreed on recommendations plus a step-by-step algorithm.
Stopping can be considered when the eye shows no fluid, no sight loss, and no new bleeding across at least three visits at the longest treatment interval a clinic uses. People whose disease stays active, or who rely on one good eye and have relapsed before, may do better continuing. After stopping, scan and vision checks should continue at an agreed pace set with the patient, since the disease can wake again.
Catalog record
| CREATOR | Günhal Şatırtav, Monica Karin Lövestam-Adrian, Woohyok Chang, Martín Charles, Lee-Jen Chen, Chui Ming Gemmy Cheung, Laurent Kodjikian, Masahito Ohji, Martin Zinkernagel, Sebastian Wolf |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 47430 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |